<DOC>
	<DOCNO>NCT00616538</DOCNO>
	<brief_summary>Novel therapy AD avoid immunosuppression potential carcinogensis need . EpiCeram™ , topical cream , represent novel class therapy skin disorder contain corticosteroid anti-inflammatory drug . The objective present study demonstrate safety efficacy EpiCeram ™ treatment moderate severe atopic dermatitis compare mid-strength topical steroid cream follow twice daily dose four week pediatric patient AD . The potential benefit patient lie potential EpiCeram ™ provide restoration normal skin barrier show previous study eliminate reduce requirement supplemental topical steroid administration .</brief_summary>
	<brief_title>Epiceram™ Device Versus Mid-Strength Topical Steroid ( Fluticasone Propionate 0.05 % ) Treatment Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Decanoic acid</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Subjects willing provide write informed consent ( i.e . assent parental/guardian consent age &gt; 7 18 year parental consent age 6 month 7 year ) participate study Males Females Age : 6 month 18 year Diagnosis Moderate Severe Atopic Dermatitis ( AD ) basis criterion define RajkaLangland Severity Index Subjects mild AD define RajkaLaneland Severity Index . Subjects great 20 % BSA measure SCORAD `` Extent '' ( A ) score ( total amount body surface area require application either Cutivate® EpiCeram® exceed 20 % ) Subjects unstable uncontrolled medical condition could require intensive treatment course study . Subjects require great 2mg per day inhale intranasal steroid . Subjects currently participate , participate another investigational drug/device trial within past month . Subjects know allergy hypersensitivity EpiCeram™ Fluticasone Cetaphil . Active infection type start study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Atopic</keyword>
	<keyword>Dermatitis</keyword>
	<keyword>eczema</keyword>
	<keyword>skin barrier</keyword>
	<keyword>ceramide</keyword>
	<keyword>topical</keyword>
	<keyword>inflamation</keyword>
	<keyword>steroid</keyword>
	<keyword>SCORAD</keyword>
	<keyword>glucocorticoid</keyword>
	<keyword>EpiCeram</keyword>
	<keyword>Cutivate</keyword>
	<keyword>fluticasone</keyword>
</DOC>